Rhythm Pharmaceuticals Inc
RYTM
Company Profile
Business description
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Contact
222 Berkeley Street
12th Floor
BostonMA02116
USAT: +1 857 264-4280
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
283
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.80 | 0.10 | 0.00% |
| CAC 40 | 8,330.97 | 16.23 | -0.19% |
| DAX 40 | 25,314.87 | 105.79 | -0.42% |
| Dow JONES (US) | 49,031.18 | 160.81 | -0.33% |
| FTSE 100 | 10,184.35 | 47.00 | 0.46% |
| HKSE | 26,999.81 | 151.34 | 0.56% |
| NASDAQ | 23,389.25 | 320.62 | -1.35% |
| Nikkei 225 | 54,341.23 | 792.07 | 1.48% |
| NZX 50 Index | 13,757.71 | 101.66 | 0.74% |
| S&P 500 | 6,905.53 | 58.21 | -0.84% |
| S&P/ASX 200 | 8,820.60 | 1.20 | -0.01% |
| SSE Composite Index | 4,126.09 | 12.67 | -0.31% |